Autoimmune diseases: similar molecular signatures in target tissues

January 07, 2021

Autoimmune diseases are diseases of "mistaken identity", where the immune system - which is supposed to protect us against infectious diseases and neoplasias - mistakenly attacks and destroys components of our own body. The incidence of autoimmune diseases is increasing on a worldwide basis, and these diseases - including type 1 diabetes (T1D), systemic lupus erythematosus (SLE), multiple sclerosis (MS) and rheumatoid arthritis (RA) - now affect up to 5% of the population in different regions. There is no cure for autoimmune diseases, and while the immune target of T1D, SLE, MS, and RA are distinct, they share several similar elements, including up to 50% common genetic risk, chronic local inflammation and mechanisms mediating target tissue damage.

In spite of these common features, autoimmune disorders are traditionally studied independently and with a focus on the immune system rather than on the target tissues. There is, however, increasing evidence that the target tissues of these diseases are not innocent bystanders of the autoimmune attack but participate in a deleterious dialogue with the immune system that contributes to their own demise, as first shown by the Eizirik's group for T1D. Furthermore, in T1D, several of the risk genes for the disease act at the target tissue level - in this case pancreatic β-cells - regulating the responses to viral infections, the dialogue with the immune system and apoptosis. Against this background, the Authors hypothesized that key inflammation-induced mechanisms, potentially shared between T1D, SLE, MS and RA, may drive similar molecular signatures at the target tissue level. Discovering these similar (or, in some cases, divergent) disease-specific signatures may allow the identification of key pathways that could be targeted for therapy, including the re-purposing of drugs already in clinical use for other diseases.

To test this hypothesis, they obtained RNA sequencing datasets (i.e. studies where all genes expressed on a diseased tissue, as compared to a healthy one, are identified) from pancreatic β-cells from controls or individuals affected by T1D, from kidney cells from controls or individuals affects by SLE, from optic chiasm from controls or individuals affected by MS and from joint tissue from controls or individuals affected by RA. These studies indicate major common gene expression changes at the target tissues of the four autoimmune disease evaluated, many of them downstream of interferons, and massive expression of candidate genes (>80% in all cases). One candidate gene in common between the four diseases is TYK2, a protein that regulates interferon signaling, and the Eizirik's group showed that use of TYK2 inhibitors - already in use for other autoimmune diseases - protect beta-cells against immunemediated damage in pre-clinical models of diabetes.
-end-


Université libre de Bruxelles

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.